We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+50.65%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$5.42B
AUM Growth
+$1.85B
Cap. Flow
+$509M
Cap. Flow %
9.4%
Top 10 Hldgs %
46.89%
Holding
89
New
20
Increased
11
Reduced
36
Closed
9
Avg Time Held
1.2 years
Top 10 Avg Time Held
1.2 years
Top 20 Avg Time Held
1 year

Top Buys

Rank Stock Value
1
ADCT icon
ADC Therapeutics
ADCT
+$210M
2
BNTX icon
BioNTech
BNTX
+$145M
3
IMMU
Immunomedics Inc
IMMU
+$102M
4
PLRX icon
Pliant Therapeutics
PLRX
+$90.5M
5
RPTX icon
Repare Therapeutics
RPTX
+$76.6M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$128M
2
QURE icon
uniQure
QURE
+$90.1M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$75.7M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$56.7M
5
CNC icon
Centene
CNC
+$49M

Sector Composition

Rank Sector Weight
1 Healthcare 98.59%
2 Industrials 1.02%
3 Financials 0.23%
4 Miscellaneous 0.16%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
SNY icon
26
Sanofi
SNY
$96.5B
$62.6M 1.16%
+1,225,500
New +$59.6M
2020 Q2
0 quarters
STOK icon
27
Stoke Therapeutics
STOK
$1.59B
$59.6M 1.1%
2,502,306
+336,368
+16% +$7.99M
2019 Q2
4 quarters
NVRO icon
28
DELISTED
NEVRO CORP.
NVRO
$59.5M 1.1%
497,764
-208,662
-30% -$24.7M
2019 Q1
5 quarters
KRYS icon
29
Krystal Biotech
KRYS
$9.77B
$58.4M 1.08%
1,409,745
+357,945
+34% +$17.2M
2018 Q4
6 quarters
TCDA
30
DELISTED
Tricida, Inc. Common Stock
TCDA
$58.2M 1.08%
2,119,000
-7,600
-0.4% -$207K
2018 Q2
8 quarters
QURE icon
31
uniQure
QURE
$1.56B
$56.2M 1.04%
1,247,135
-1,526,390
-55% -$90.1M
2018 Q2
8 quarters
IMGN icon
32
DELISTED
Immunogen Inc
IMGN
$55.2M 1.02%
12,006,979
-4,726,900
-28% -$20.1M
2017 Q1
13 quarters
CYRX icon
33
CryoPort
CYRX
$865M
$55M 1.02%
1,817,663
– –
2019 Q4
2 quarters
SRRK icon
34
Scholar Rock
SRRK
$4.94B
$52.4M 0.97%
2,875,889
-14,200
-0.5% -$242K
2018 Q2
8 quarters
PPD
35
DELISTED
PPD, Inc. Common Stock
PPD
$51.8M 0.96%
1,933,473
+642,641
+50% +$16.1M
2020 Q1
1 quarter
AMED icon
36
DELISTED
Amedisys
AMED
$44.9M 0.83%
226,165
+48,600
+27% +$9.06M
2019 Q2
4 quarters
DVAX icon
37
DELISTED
Dynavax Technologies
DVAX
$44.9M 0.83%
+5,062,100
New +$25.6M
2020 Q2
0 quarters
BIIB icon
38
Biogen
BIIB
$34.8B
$43.4M 0.8%
162,300
-427,000
-72% -$128M
2019 Q4
2 quarters
AXNX icon
39
DELISTED
Axonics, Inc. Common Stock
AXNX
$41.9M 0.77%
1,192,100
-315,300
-21% -$10.9M
2018 Q4
6 quarters
MRK icon
40
Merck
MRK
$359B
$40.5M 0.75%
549,466
-276,882
-34% -$20.8M
2020 Q1
1 quarter
DXCM icon
41
DexCom
DXCM
$33.1B
$39.4M 0.73%
389,200
-128,000
-25% -$11.4M
2020 Q1
1 quarter
NVS icon
42
Novartis
NVS
$286B
$38.4M 0.71%
439,800
-213,800
-33% -$18.5M
2019 Q4
2 quarters
ICUI icon
43
ICU Medical
ICUI
$4.18B
$37.1M 0.69%
+201,400
New +$40M
2020 Q2
0 quarters
GMAB icon
44
Genmab
GMAB
$23.2B
$35.8M 0.66%
1,057,393
-491,607
-32% -$13.4M
2019 Q3
3 quarters
BSX icon
45
Boston Scientific
BSX
$64B
$31.5M 0.58%
+897,355
New +$32.3M
2020 Q2
0 quarters
UNH icon
46
UnitedHealth
UNH
$365B
$30.6M 0.57%
103,900
-137,200
-57% -$39.3M
2016 Q3
15 quarters
CTLT icon
47
DELISTED
CATALENT, INC.
CTLT
$30.3M 0.56%
413,100
-93,200
-18% -$6.33M
2020 Q1
1 quarter
LMNX
48
DELISTED
Luminex Corp
LMNX
$29.9M 0.55%
+917,907
New +$29M
2020 Q2
0 quarters
EIDX
49
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$28.3M 0.52%
593,842
-95,636
-14% -$4.45M
2018 Q2
8 quarters
ZYME icon
50
Zymeworks
ZYME
$1.85B
$28.3M 0.52%
783,500
-85,100
-10% -$3.13M
2020 Q1
1 quarter
1
2
3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2020 Portfolio in Review

As of Q2 2020, Redmile Group held 89 positions worth $5.42B, up 52% from $3.57B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Redmile Group deployed $509M of net new capital in Q2 2020, opening 20 new positions and adding to 11 existing holdings. Its largest new stake was ADC Therapeutics: 5,525,870 shares worth $259M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Biogen, an estimated $128M trimmed.

  • Redmile Group's largest Q2 2020 buy was ADC Therapeutics: 5,525,870 shares worth $259M.
  • Redmile Group added most to BioNTech in Q2 2020, an estimated $145M increase.
  • Redmile Group's biggest Q2 2020 reduction was Biogen, cutting an estimated $128M.
  • Redmile Group fully exited Seagen Inc. Common Stock in Q2 2020, selling an estimated $75.7M.
  • Redmile Group's ten largest holdings make up 47% of its $5.42B portfolio in Q2 2020.
  • Redmile Group opened 20 new positions and closed 9 in Q2 2020.
  • Redmile Group's portfolio value rose 52% quarter-over-quarter to $5.42B.

Based on Redmile Group's 13F filing for Q2 2020, filed 14 Aug 2020.